NVP-BVU972
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406788

CAS#: 1185763-69-2

Description: NVP-BVU972, also known as BVN-972, is a selective and potent inhibitor of c-Met with IC50 of 14 nM. BVN-972 displays IC50 values more than 1000 nM in other kinases such as the most closely related kinase recepteur d'origine nantais (RON).


Price and Availability

Size
Price

10mg
USD 710
Size
Price

50mg
USD 1860
Size
Price

NVP-BVU972, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406788
Name: NVP-BVU972
CAS#: 1185763-69-2
Chemical Formula: C20H16N6
Exact Mass: 340.1436
Molecular Weight: 340.39
Elemental Analysis: C, 70.57; H, 4.74; N, 24.69


Synonym: NVP-BVU972; NVP-BVU 972; NVP-BVU-972; BVU-972; BVU 972; BVU972.

IUPAC/Chemical Name: 6-[[6-(1-methylpyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl]methyl]quinoline

InChi Key: RNCNPRCUHHDYPC-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H16N6/c1-25-13-16(11-23-25)19-6-7-20-22-12-17(26(20)24-19)10-14-4-5-18-15(9-14)3-2-8-21-18/h2-9,11-13H,10H2,1H3

SMILES Code: CN1N=CC(C2=NN3C(C=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Shin JS, Hong SW, Moon JH, Kim JS, Jung KA, Kim SM, Lee DH, Kim I, Yoon SJ,
Lee CG, Choi EK, Lee JY, Kim KP, Hong YS, Lee JL, Kim B, Choi EK, Lee JS, Jin DH,
Kim TW. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and
its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99. doi:
10.1007/s10637-013-0039-4. Epub 2013 Oct 31. PubMed PMID: 24173966.

2: Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E,
Ruddy DA, Monahan JE, Jones MD, Blank J, Haasen D, Drueckes P, Wartmann M,
McCarthy C, Sellers WR, Hofmann F. A drug resistance screen using a selective MET
inhibitor reveals a spectrum of mutations that partially overlap with activating
mutations found in cancer patients. Cancer Res. 2011 Aug 1;71(15):5255-64. doi:
10.1158/0008-5472.CAN-10-4433. Epub 2011 Jun 22. PubMed PMID: 21697284.